标题：宫颈癌患者卵巢移位术后化疗期间卵巢功能变化临床观察

      作者：王雯智 1，石建勇 1，郑蕾 2    1.陕西省人民医院妇科，陕西 西安 710068；2.西安医学院药学院，陕西 西安 710021

      卷次： 2019年30卷8期

      【摘要】 目的 探讨宫颈癌患者卵巢移位术后化疗期间卵巢功能变化。方法 选取2017年1月至2018年3月陕西省人民医院妇科收治的50例卵巢移位术后化疗的宫颈癌患者为研究对象，化疗后6个月，采用化学发光法测定50例宫颈癌患者血清卵泡刺激素表达水平，根据测定结果将其分为卵巢功能正常组(n=25)、卵巢功能异常组(n=25)。测定并比较两组患者化疗前后血清卵泡刺激素、黄体生成激素、雌二醇水平，同时比较两组患者的年龄、BMI指数及移位卵巢位置。结果 化疗前及化疗后，卵巢功能异常组患者的血清卵泡刺激素水平为(8.14±0.58) IU/L，明显高于卵巢功能正常组的(5.02±0.63) IU/L，差异有统计学意义(P<0.05)；化疗6个月后，卵巢功能异常组和卵巢功能正常组患者血清卵泡刺激素[(8.14±0.58) IU/L vs (5.02±0.63) IU/L]、黄体生成激素[(33.21±6.70) IU/L vs (7.59±1.38) IU/L]比较，卵巢功能异常组高于卵巢功能正常组，血清雌二醇水平 [(430.72±70.80) pmol/L vs (785.36±128.67) pmol/L]比较，卵巢功能异常组低于卵巢功能正常组，差异均有统计学意义(P<0.05)；两组患者的BMI指数比较差异无统计学意义(P>0.05)；卵巢功能异常组患者年龄为(38.79±5.01)岁，明显高于卵巢功能正常组的(32.28±4.89)岁，差异有统计学意义(P<0.05)；卵巢功能异常组患者移位卵巢位置为(1.82±0.31) cm，明显大于卵巢功能正常组的(1.30±0.22) cm，差异有统计学意义(P<0.05)。结论 宫颈癌患者卵巢移位术后化疗期间可能出现卵巢功能下降或卵巢功能丧失。
      【关键词】 宫颈癌；卵巢移位术；化疗；卵巢功能；卵泡刺激素
      【中图分类号】 R737.33 【文献标识码】 A 【文章编号】 1003—6350（2019）08—1028—03

Changes of ovarian function in patients with cervical cancer during chemotherapy after ovarian transposition.WANG Wen-zhi 1, SHI Jian-yong 1, ZHENG Lei 2.
1. Department of Gynecology, the People's Hospital of Shaanxi Province,Xi'an 710068, Shaanxi, CHINA; 2. College of Pharmacy, Xi’an Medical University, Xi'an 710021, Shaanxi, CHINA
【Abstract】 Objective To investigate the changes of ovarian function in patients with cervical cancer duringchemotherapy after ovarian transposition. Methods From January 2017 to March 2018, 50 patients with cervical can-cer who received chemotherapy after ovarian translocation in the Department of Gynecology, the People's Hospital ofShaanxi Province were selected as subjects. Six months after chemotherapy, the levels of serum follicle stimulating hor-mone (FSH) in the 50 patients were determined by chemiluminescence method. According to the results, the patientswere divided into normal ovarian function group (n=25) and abnormal ovarian function group (n=25). The levels of se-rum FSH, luteinizing hormone, and estradiol were measured and compared before and after treatment between thetwo groups. The age, body mass index (BMI), and the location of ovaries were compared between the two groups.Results Before and after chemotherapy, the level of serum FSH in patients with abnormal ovarian function was higherthan that in patients with normal ovarian function: (8.14±0.58) IU/L vs (5.02±0.63) IU/L (P<0.05). After 6 months of che-motherapy, the levels of serum FSH and luteinizing hormone in patients with abnormal ovarian function were higherthan those in patients with normal ovarian function: (8.14±0.58) IU/L vs (5.02±0.63) IU/L, (33.21±6.70) IU/L vs (7.59±1.38) IU/L; serum estradiol levels were lower than that in patients with normal ovarian function: (430.72±70.80) pmol/Lvs (785.36±128.67) pmol/L; the differences were statistically significant between the two groups (P<0.05). There was nosignificant difference in BMI index between the two groups (P>0.05). The age of the subjects with abnormal ovarian func-tion was significantly higher than that of the normal ovarian function group: (38.79±5.01) years vs (32.28±4.89) years, P<0.05. The location of ovarian translocation in the abnormal ovarian function group was significantly larger than that inthe normal ovarian function group: (1.82±0.31) cm vs (1.30±0.22) cm, P<0.05. Conclusion Ovarian dysfunction orloss of ovarian function may occur in patients with cervical cancer during chemotherapy after ovarian transposition.
      【Key words】 Cervical cancer; Ovarian transposition; Chemotherapy; Ovarian function; Follicle stimulating hor-mone (FSH)